...a U.S. patent covering the use of its bioresorbable polymer technology to prevent post-operative adhesions. Life Medical...

...as an addition to a patient's fat cells for injection as a soft tissue filler. Life Medical...

...Pathfinder completed its reverse-merger with biomaterials company SyntheMed. The combined company, Pathfinder Cell Therapy Inc...
...in Cambridge, Mass. and will begin trading on the OTCBB shortly (see BioCentury, Jan. 3). SyntheMed Inc....

...incorporated into the new tissue. Last December, Pathfinder said it would reverse-merge with biomaterials company SyntheMed Inc....

...Pathfinder will reverse-merge with biomaterials company SyntheMed in a stock deal. Pathfinder shareholders will own about...
...Cell Therapy Inc. and headquartered in Cambridge, Mass., with SyntheMed shareholders owning the remaining 20%. SyntheMed...
...sole manager and SyntheMed's board, and is subject to approval by SyntheMed and Pathfinder shareholders. SyntheMed Inc....

...and other countries, and in the U.S. for use in pediatric patients following open-heart surgery. SyntheMed Inc....

...Raptor Pharmaceutical Corp. (OTCBB:RPTP), Novato, Calif. Business: Neurology, Metabolic, Cancer Appointed: Richard Franklin, chairman of Synthemed Inc. WIR...

...for the polymer-based bioresorbable adhesion barrier film is under FDA review (see BioCentury, April 2). SyntheMed Inc....